---

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 11, 2003

 

---

 

HOLLIS-EDEN PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

---

 

000-24672

(Commission File No.)

 

Delaware		13-3697002
(State or other jurisdiction of incorporation)		(IRS Employer Identification No.)

 

4435 Eastgate Mall, Suite 400

San Diego, California 92121

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (858) 587-9333

 

---

---

ITEM 5.

OTHER EVENTS.

 

On August 11, 2003, Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (“Hollis-Eden”), issued a press release announcing the conversion of all of its outstanding convertible debentures into 1,675,581 shares of Hollis-Eden common stock, including accrued interest. See Exhibit 99.1 for the text of the press release.

 

ITEM 7.

FINANCIAL STATEMENTS AND EXHIBITS.

 

EXHIBITS.

 

99.1		Press release issued on August 11, 2003 by Hollis-Eden.

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

						HOLLIS-EDEN PHARMACEUTICALS, INC.
Dated:		August 11, 2003				By:		/s/    ERIC J. LOUMEAU
								Eric J. Loumeau Vice President, General Counsel

---

INDEX TO EXHIBITS

 

99.1		Press  Release issued on August 11, 2003 by Hollis-Eden Pharmaceuticals, Inc.